Fmr LLC Sells 14,064 Shares of Certara, Inc. (NASDAQ:CERT)

Fmr LLC lessened its stake in Certara, Inc. (NASDAQ:CERT) by 4.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 277,235 shares of the company’s stock after selling 14,064 shares during the period. Fmr LLC owned about 0.17% of Certara worth $3,246,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of CERT. Brown Brothers Harriman & Co. bought a new position in Certara during the third quarter worth $27,292,000. Massachusetts Financial Services Co. MA boosted its position in shares of Certara by 40.7% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,901,898 shares of the company’s stock worth $45,691,000 after purchasing an additional 1,128,006 shares in the last quarter. Daventry Group LP grew its stake in shares of Certara by 153.0% in the 2nd quarter. Daventry Group LP now owns 1,308,572 shares of the company’s stock valued at $18,124,000 after buying an additional 791,405 shares during the period. Kopion Asset Management LLC bought a new stake in Certara in the 3rd quarter valued at about $4,457,000. Finally, Sei Investments Co. raised its stake in Certara by 39.5% during the 2nd quarter. Sei Investments Co. now owns 997,871 shares of the company’s stock worth $13,821,000 after buying an additional 282,357 shares during the period. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Trading Down 2.0 %

Shares of Certara stock opened at $11.47 on Friday. The stock’s 50-day simple moving average is $10.84 and its 200 day simple moving average is $12.66. Certara, Inc. has a 52-week low of $9.41 and a 52-week high of $19.87. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. The stock has a market capitalization of $1.85 billion, a P/E ratio of -57.35, a P/E/G ratio of 5.86 and a beta of 1.53.

Certara (NASDAQ:CERT) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. The business had revenue of $94.80 million during the quarter, compared to analyst estimates of $95.51 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. Certara’s revenue was up 10.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.06 EPS. As a group, research analysts anticipate that Certara, Inc. will post 0.28 EPS for the current year.

Insider Activity

In related news, insider Patrick F. Smith sold 5,409 shares of the stock in a transaction on Monday, October 7th. The stock was sold at an average price of $11.03, for a total value of $59,661.27. Following the sale, the insider now owns 50,091 shares in the company, valued at approximately $552,503.73. This trade represents a 9.75 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 2.39% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on CERT shares. UBS Group raised Certara from a “neutral” rating to a “buy” rating and set a $16.00 price objective for the company in a research note on Friday, September 27th. Barclays decreased their price objective on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a report on Thursday, November 7th. Finally, Robert W. Baird dropped their target price on shares of Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 5th. Six equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $15.92.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.